Neuren Pharmaceuticals Limited
ASX:NEU.AX
12.27 (AUD) • At close November 5, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Neuren Pharmaceuticals Limited |
Symbool | NEU.AX |
Munteenheid | AUD |
Prijs | 12.27 |
Beurswaarde | 1,568,302,320 |
Dividendpercentage | 0% |
52-weken bereik | 12.02 - 25.95 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Jonathan Charles Pilcher A.C.A., ACA, B.Sc., BSc (Hons), F.C.A. |
Website | https://www.neurenpharma.com |
An error occurred while fetching data.
Over Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (AUD)
Cijfers zijn in miljoenen (AUD)